EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC 4.0

Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G

Marie V Nelson, AeRang Kim iD, P Mickey Williams, Sinchita Roy-Chowdhuri, David R Patton, Brent D Coffey, Joel M Reid, Jin Piao, Lauren Saguilig, Todd A Alonzo, Stacey L Berg, Nilsa C Ramirez und 10 weitere

The Oncologist · 2024

DOI: 10.1093/oncolo/oyae119 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Oncologist, 2024. Verfasst von Marie V Nelson und 21 weiteren Autor:innen. Beteiligte Einrichtung: Children's National Hospital, Washington, DC 20010, United States. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Vemurafenib, Mutation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This is a phase II subprotocol of the NCI-COG Pediatric MATCH study evaluating vemurafenib, a selective oral inhibitor of BRAF V600 mutated kinase, in patients with relapsed or refractory solid tumors harboring BRAF V600 mutations.

Methods

Patients received vemurafenib at 550 mg/m2 (maximum 960 mg/dose) orally twice daily for 28-day cycles until progression or intolerable toxicity. The primary aim was to determine the objective response rate and secondary objectives included estimating progression-free survival and assessing the tolerability of vemurafenib.

Results

Twenty-two patients matched to the subprotocol and 4 patients (18%) enrolled. Primary reasons for non-enrollment were ineligibility due to exclusions of low-grade glioma (n = 7) and prior BRAF inhibitor therapy (n = 7). Enrolled diagnoses were one each of histiocytosis, ameloblastoma, Ewing sarcoma, and high-grade glioma, all with BRAF V600E mutations. Treatment was overall tolerable with mostly expected grade 1/2 adverse events (AE). Grade 3 or 4 AE on treatment were acute kidney injury, hyperglycemia, and maculopapular rash. One patient came off therapy due to AE. One patient (glioma) had an objective partial response and remained on protocol therapy for 15 cycles.

Conclusion

There was a low accrual rate on this MATCH subprotocol, with only 18% of those who matched with BRAFV600 mutations enrolling, resulting in early termination, and limiting study results (ClinicalTrials.gov Identifier: NCT03220035).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins B-rafVemurafenibMutationHumansMaleFemaleChildAdolescentYoung AdultAdultChild, PreschoolNeoplasms

Stichwörter der Autor:innen

BRAF V600 mutationspediatric matchvemurafenib

Substanzen

Proto-Oncogene Proteins B-rafVemurafenibBRAF protein, human

Autor:innen und Institutionen

  • Children's National Hospital, Washington, DC 20010, United States.
  • Frederick National Laboratory for Cancer Research, Frederick MD 21701, United States.
  • University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
  • Center for Biomedical Informatics and Information Technology, NCI, NIH, Bethesda, MD 20892, United States.
  • Mayo Clinic, Rochester, MN 55905, United States.
  • Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, United States.

ORCID-Profile: AeRang Kim, Douglas S Hawkins, Margaret M Mooney

Förderung

  • NCI NIH HHS

Zitieren

APA

Nelson, M. V., Kim, A., Williams, P. M., Roy-Chowdhuri, S., Patton, D. R., Coffey, B. D., Reid, J. M., Piao, J., Saguilig, L., Alonzo, T. A., Berg, S. L., Ramirez, N. C., Jaju, A., Fox, E., Weigel, B. J., Hawkins, D. S., Mooney, M. M., Takebe, N., Tricoli, J. V., …, & Parsons, D. W. (2024). Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G. The Oncologist. https://doi.org/10.1093/oncolo/oyae119

Vancouver

Nelson MV, Kim A, Williams PM, Roy-Chowdhuri S, Patton DR, Coffey BD, et al. Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G. The Oncologist. 2024. doi:10.1093/oncolo/oyae119

BibTeX
@article{Nelson2024,
  author = {Nelson, Marie V and Kim, AeRang and Williams, P Mickey and Roy-Chowdhuri, Sinchita and Patton, David R and Coffey, Brent D and Reid, Joel M and Piao, Jin and Saguilig, Lauren and Alonzo, Todd A and Berg, Stacey L and Ramirez, Nilsa C and Jaju, Alok and Fox, Elizabeth and Weigel, Brenda J and Hawkins, Douglas S and Mooney, Margaret M and Takebe, Naoko and Tricoli, James V and Janeway, Katherine A and Seibel, Nita L and Parsons, D Williams},
  title = {Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G},
  journal = {The Oncologist},
  year = {2024},
  doi = {10.1093/oncolo/oyae119}
}
Kostenlos starten →